On December 7, 2021, the first International Health Industry Innovation and Entrepreneurship Exchange Competition and the second Yangtze River Delta Translational Medicine Innovation and Entrepreneurship Competition Jiangsu Division Competition was held in Nanjing Xuzhuang High-tech Zone. Nanjing Sunway Biomedical Technology Co., Ltd. research and development project "blood pathogen inactivation treatment system" won the third prize of the enterprise group.

This competition is co-sponsored by the Nanjing Xuanwu District Committee of the Communist Party of China and the People's Government of Nanjing Xuanwu District, and jointly organized by the Party Working Committee of Xuzhuang High-tech Zone, Xuzhuang High-tech Zone Management Committee, and Jiangsu Gaochun Economic Development Zone. The innovation vitality and transformation capabilities of medical personnel, colleges and universities, strengthen the connection between innovation and clinical application and financial capital, and deepen the cooperation in the production, learning, research and use of medical device industry, build a more efficient and practical innovation service platform to promote the continuous innovation and development of regional medical device industry.

The "Blood Pathogen Inactivation Treatment System" project of Shuangwei Biology went through layers of selection in the preliminary competition and was finally shortlisted for the Jiangsu competition. The competition invited heavyweight experts in the medical field as judges to strictly control the quality of the project and synthesize various indicators to select high-quality projects. After fierce competition, the "blood pathogen inactivation treatment system" of Sunway Biology came to the fore and won the third prize in the enterprise group of this competition.

The blood pathogen inactivation treatment system is a joint project developed by Sunway Biology and the only national blood transfusion research institute in my country-the Institute of Blood Transfusion of the Chinese Academy of Medical Sciences. The project uses riboflavin photochemical method to treat donated blood to eliminate The risk of blood transfusion caused by pathogens ensures the safety of blood transfusion. The project fills the domestic blank, and is more simple, safe and effective than the pathogen inactivation method used in the current market!

The award of "blood pathogen inactivation treatment system" not only affirms the R & D and innovation level of Sunway biology, but also is of great significance to stimulate the sustainable development of medical device health industry. In the future, Sunway Biology will continue to uphold the concept of "integrity, pragmatism, innovation, and transcendence", committed to the continuous development of human health, and make due contributions to society!

Contributor: Wang Fang

typesetting: shi jun